
From Lab to Jab: the economic case for the UK’s vaccine capabilities
New research from Public First, commissioned by the Tony Blair Institute, sets out the economic case for protecting the UK’s domestic vaccine manufacturing base, and the price of failing to secure the full path from lab to jab in the next pandemic. Using new supply-chain and labour-market analysis alongside survival




